Cited by 2,292Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

C-Reactive Protein Levels and Outcomes after Statin Therapy

Open access

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine

DOI 10.1056/nejmoa042378

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa042378

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citation
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citation
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

Davignon J, 2004, Circulation, 109, III

Sorted by citations

Items 501–600 of 1,000

Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal–medial thickness in patients with coronary heart disease
Yu, C., Zhang, Q., Lam, L., Lin, H., Kong, S. L., Chan, W., Fung, J. W.-H., Cheng, K. K. K., Chan, I. H. S., Lee, S. W.-L., et al. (2007) · Heart · doi:10.1136/hrt.2006.102848 · Cited by 73
Molecular Pathways Regulating Macrophage Polarization: Implications for Atherosclerosis
Hoeksema, M. A., Stöger, J. L., & de Winther, M. P. J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0240-5 · Cited by 77
Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm
Ishii, M., Kaikita, K., Sato, K., Yamanaga, K., Miyazaki, T., Akasaka, T., Tabata, N., Arima, Y., Sueta, D., Sakamoto, K., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003426 · Cited by 74
C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?
Lavie, C. J., Milani, R. V., Verma, A., & O’Keefe, J. H. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181c61b66 · Cited by 72
Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients
Murphy, D. M., Forrest, I., Corris, P. A., Johnson, G. E., Small, T., Jones, D., Fisher, A. J., Egan, J. J., Cawston, T. E., Ward, C., et al. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00386.2007 · Cited by 72
Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease
Nylænde, M., Kroese, A., Stranden, E., Morken, B., Sandbæk, G., Lindahl, A., Arnesen, H., & Seljeflot, I. (2006) · Vascular Medicine · doi:10.1191/1358863x06vm662oa · Cited by 71
Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients
Li, J., Pan, Y., Xu, J., Li, S., Wang, M., Quan, K., Meng, X., Li, H., Lin, J., Wang, Y., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.033152 · Cited by 72
Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: Effect of statins on let-7i and Toll-like receptor 4 signal
Satoh, M., Tabuchi, T., Minami, Y., Takahashi, Y., Itoh, T., & Nakamura, M. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.08.005 · Cited by 72
The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery
Edwards, A. V. G., White, M. Y., & Cordwell, S. J. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r800007-mcp200 · Cited by 73
American Diabetes Association Indications for Statins in Diabetes
Eldor, R., & Raz, I. (2009) · Diabetes Care · doi:10.2337/dc09-s345 · Cited by 71
Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)
Milionis, H. J., Rizos, E. C., Kostapanos, M. S., Filippatos, T. D., Gazi, I. F., Ganotakis, E. S., Goudevenos, J. A., Mikhailidis, D. P., & Elisaf, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112462 · Cited by 71
Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users
DeCensi, A., Gandini, S., Serrano, D., Cazzaniga, M., Pizzamiglio, M., Maffini, F. A., Pelosi, G., Daldoss, C., Omodei, U., Johansson, H. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4318 · Cited by 71
Benefit of Intensive Statin Therapy in Women
Truong, Q. A., Murphy, S. A., McCabe, C. H., Armani, A. M., & Cannon, C. P. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957720 · Cited by 73
Self-citation
Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS
Ray, K. K. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl180 · Cited by 71
Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies
Pirro, M., Simental‐Mendía, L. E., Bianconi, V., Watts, G. F., Banach, M., & Sahebkar, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010118 · Cited by 73
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
Cooreman, M. P., Butler, J., Giugliano, R. P., Zannad, F. M., Dzen, L., Huot-Marchand, P., Baudin, M., Beard, D. R., Junien, J., Broqua, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47919-9 · Cited by 75
Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function
Isbel, N. M., Haluska, B. A., Johnson, D. W., Beller, E., Hawley, C. M., & Marwick, T. H. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.017 · Cited by 70
Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double‐blind, placebo‐controlled trial
Mok, C. C., Wong, C. K., To, C. H., Lai, J. P. S., & Lam, C. S. (2011) · Arthritis Care & Research · doi:10.1002/acr.20440 · Cited by 71
C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?
Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., & Talmud, P. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.115923 · Cited by 70
Cardiovascular Disease in Transplant Recipients
Gill, J. S. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02690707 · Cited by 69
Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents
Shen, J., & Ordovás, J. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.117754 · Cited by 71
Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes
LENDERINK, T. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl125 · Cited by 70
Controversies in stable coronary artery disease
Opie, L. H., Commerford, P., & Gersh, B. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67927-0 · Cited by 69
C-Reactive Protein: A Family of Proteins to Regulate Cardiovascular Function
Schwedler, S. B., Filep, J. G., Galle, J., Wanner, C., & Potempa, L. A. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.028 · Cited by 68
Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome
Oemrawsingh, R. M., Lenderink, T., Akkerhuis, K. M., Heeschen, C., Baldus, S. E., Fichtlscherer, S., Hamm, C. W., Simoons, M. L., & Boersma, E. H. (2011) · Heart · doi:10.1136/hrt.2010.197392 · Cited by 68
Further evidence for sustained systemic inflammation in xenograft recipients ( SIXR )
Iwase, H., Ekser, B., Zhou, H., Liu, H., Satyananda, V., Humar, R., Humar, P., Hara, H., Long, C. E., Bhama, J. K., et al. (2015) · Xenotransplantation · doi:10.1111/xen.12182 · Cited by 68
The long-term predictive value of the neutrophil-to-lymphocyte ratio in Type 2 diabetic patients presenting with acute myocardial infarction
Lee, G. K., Lee, L. C., Chong, E. Y., Lee, C., Teo, S.-G., Chia, B. L., & Poh, K. K. (2012) · QJM · doi:10.1093/qjmed/hcs123 · Cited by 68
Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease
Ardigò, D., Assimes, T. L., Fortmann, S. P., Go, A. S., Hlatky, M. A., Hytopoulos, E., Iribarren, C., Tsao, P. S., Tabibiazar, R., & Quertermous, T. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00104.2007 · Cited by 68
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism
Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.021 · Cited by 67
Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome
Katsioupa, M., Kourampi, I., Oikonomou, E. K., Tsigkou, V., Theofilis, P., Charalambous, G., Marinos, G., Gialamas, I., Zisimos, K., Anastasiou, A., et al. (2023) · Life · doi:10.3390/life13101992 · Cited by 77
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study
Forst, T. M., Pfützner, A., Lübben, G., Weber, M. M., Marx, N., Karagiannis, E., Koehler, C., Baurecht, W., Hohberg, C., & Hanefeld, M. (2007) · Metabolism · doi:10.1016/j.metabol.2006.11.007 · Cited by 67
Comprehensive efforts to increase adherence to statin therapy
Vonbank, A., Agewall, S., Kjeldsen, K. P., Lewis, B. S., Torp-Pedersen, C. T., Ceconi, C., Funck‐Brentano, C., Kaski, J. C., Niessner, A., Tamargo, J. L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw628 · Cited by 72
The Nonlipid Effects of Statins on Endothelial Function
Beckman, J. A., & Creager, M. A. (2006) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.03.003 · Cited by 67
Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease
Steven, S., Münzel, T. F., & Daiber, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818185 · Cited by 68
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
Xie, S., Galimberti, F., Olmastroni, E., Lüscher, T. F., Carugo, S., Catapano, A. L., Casula, M., META-LIPID Group, Catapano, A. L., Casula, M., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae034 · Cited by 71
Self-citation
Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: Evidence for depression-induced atherosclerotic risk
Waldman, W. J., Williams, M. V., Lemeshow, S. A., Binkley, P. F., Guttridge, D. C., Kiecolt‐Glaser, J. K., Knight, D. A., Ladner, K. J., & Glaser, R. (2007) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2007.07.007 · Cited by 68
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome
Gaztañaga, J., Farkouh, M. E., Rudd, J. H. F., Brotz, T. M., Rosenbaum, D. H., Mani, V., Kerwin, T. C., Taub, R. A., Tardif, J., Tawakol, A. A., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.027 · Cited by 68
Relation Between C-Reactive Protein, Homocysteine Levels, Fibrinogen, and Lipoprotein Levels and Leukocyte and Platelet Counts, and 10-Year Risk for Cardiovascular Disease Among Healthy Adults in the USA
Park, C. S., Ihm, S., Yoo, K., Kim, D., Lee, J. M., Kim, H.-Y., Chung, W.-S., Seung, K. B., & Kim, J.-H. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.045 · Cited by 66
Behçet’s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects
Becatti, M., Emmi, G., Bettiol, A., Silvestri, E., Scala, G. D., Taddei, N., Prisco, D., & Fiorillo, C. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13243 · Cited by 67
C-reactive protein induces M-CSF release and macrophage proliferation
Devaraj, S., Yun, J., Duncan‐Staley, C., & Jialal, I. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0808458 · Cited by 66
Gastric bypass reduces biochemical cardiac risk factors
Williams, D. B., Hagedorn, J. C., Lawson, E. H., Galanko, J. A., Safadi, B. Y., Curet, M. J., & Morton, J. M. (2006) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2006.10.003 · Cited by 66
Statins and C‐Reactive Protein Levels
Asher, J., & Houston, M. (2007) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.06639.x · Cited by 65
Thrombolysis In Myocardial Infarction (TIMI) Study Group
Sabatine, M. S., & Braunwald, E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.060 · Cited by 70
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 67
Self-citation
The National Institute of Dental and Craniofacial Research
Pihlstrom, B. L., & Tabak, L. A. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0256 · Cited by 66
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
Revkin, J. H., Shear, C. L., Pouleur, H. G., Ryder, S. W., & Orloff, D. G. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.1.1 · Cited by 66
Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases
Hoogeveen, R. M., Nahrendorf, M., Riksen, N. P., Netea, M. G., de Winther, M. P. J., Lutgens, E., Nordestgaard, B. G., Neidhart, M., Stroes, E. S. G., Catapano, A. L., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx581 · Cited by 65
Beyond Lipid Lowering: What Have We Learned About the Benefits of Statins from the Acute Coronary Syndromes Trials?
Ray, K. K., Cannon, C. P., & Ganz, P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.016 · Cited by 64
Self-citation
Targeting vascular risk in patients with metabolic syndrome but without diabetes
Athyros, V. G., Mikhailidis, D. P., Papageorgiou, A. A., Didangelos, T., Athanasia, P., Kleta, D., Karagiannis, A. I., Kakafika, A. I., Τζιόμαλος, Κ., & Elisaf, M. (2005) · Metabolism · doi:10.1016/j.metabol.2005.03.010 · Cited by 66
The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions
Belay, B., Belamarich, P. F., & Tom-Revzon, C. (2007) · PEDIATRICS · doi:10.1542/peds.2006-0787 · Cited by 66
Impact of cardiac rehabilitation on coronary risk factors, inflammation, and the metabolic syndrome in obese coronary patients
Lavie, C. J., Morshedi‐Meibodi, A., & Milani, R. V. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00002.x · Cited by 61
Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease
Arroyo‐Espliguero, R., y, P. A., Quiles, J., & Kaski, J. C. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.009 · Cited by 64
The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry
Kuroda, M., Otake, H., Shinke, T., Takaya, T., Nakagawa, M., Osue, T., Taniguchi, Y., Iwasaki, M., Nishio, R., Kinutani, H., et al. (2016) · EuroIntervention · doi:10.4244/eijy15m12_05 · Cited by 64
Targeting stem cells in the realm of drug-resistant breast cancer
Dey, P., Rathod, M., & De, A. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s189224 · Cited by 64
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials
Braunwald, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr310 · Cited by 64
Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications
Sterpetti, A. V. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00891-3 · Cited by 60
Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study
Belalcazar, L. M., Haffner, S. M., Lang, W., Hoogeveen, R. C., Rushing, J., Schwenke, D. C., Tracy, R. P., Pi‐Sunyer, F. X., Kriska, A. M., & Ballantyne, C. M. (2013) · Obesity · doi:10.1002/oby.20431 · Cited by 62
Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha)
Bjarnason‐Wehrens, B., Held, K., Hoberg, E., Karoff, M., & Rauch, B. (2007) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-007-0001-0 · Cited by 64
Statins and LDL‐cholesterol lowering: an overview
Stroes, E. S. G. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59102 · Cited by 67
Effect of Rosuvastatin on C-Reactive Protein and Renal Function in Patients With Chronic Kidney Disease
Verma, A. K., Ranganna, K. M., Reddy, R. S., Verma, M., & Gordon, N. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.074 · Cited by 63
Combating Inflammation in Cardiovascular Disease
Sethwala, A., Goh, I. Y., & Amerena, J. V. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.003 · Cited by 68
Cholesterol in the Cell Membrane—An Emerging Player in Atherogenesis
Paukner, K., Lesná, I. K., & Poledne, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010533 · Cited by 69
Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death
Scirica, B. M., Cannon, C. P., Sabatine, M. S., Jarolı́m, P., Sloane, S., Rifai, N., Braunwald, E., Morrow, D. A., & for the PROVE IT–TIMI 22 Investigators (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.117192 · Cited by 62
Self-citation
Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging
Lee, J., Wiesmann, F., Shirodaria, C. C., Leeson, P., Petersen, S. E., Francis, J. M., Jackson, C., Robson, M. D., Neubauer, S., Channon, K. M., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.001 · Cited by 62
C-Reactive Protein Triggers Cell Death in Ischemic Cells
Sheriff, A., Kayser, S., Brunner, P., & Vogt, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.630430 · Cited by 67
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation
Clements‐Jewery, H., Hearse, D. J., & Curtis, M. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706231 · Cited by 61
Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay
Baker, W. L., White, C. M., Kluger, J., Denowitz, A., Konecny, C. P., & Coleman, C. I. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.11.026 · Cited by 61
Inflammatory Stress Induces Statin Resistance by Disrupting 3-Hydroxy-3-Methylglutaryl-CoA Reductase Feedback Regulation
Chen, Y., Ku, H., Zhao, L., Wheeler, D. C., Li, L.-C., Li, Q., Varghese, Z., Moorhead, J. F., Powis, S. H., Huang, A., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301301 · Cited by 61
Relation of Left Ventricular Hypertrophy to Microalbuminuria and C-Reactive Protein in Children and Adolescents with Essential Hypertension
Assadi, F. K. (2007) · Pediatric Cardiology · doi:10.1007/s00246-007-9153-4 · Cited by 61
Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention
Stockley, R. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902868971 · Cited by 61
CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up
Hartford, M., Wiklund, O., Hultén, L. M., Perers, E., Person, A., Herlitz, J. D., Hurt‐Camejo, E., Karlsson, T., & Caidahl, K. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.04.004 · Cited by 61
Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis
Lacy, M., Atzler, D., Liu, R., de Winther, M. P. J., Weber, C., & Lutgens, E. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.012 · Cited by 69
Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications
Montarello, N. J., Nguyen, M. T., Wong, D. T. L., Nicholls, S. J., & Psaltis, P. J. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07106-6 · Cited by 66
Inflammation, C-Reactive Protein, and Cardiovascular Disease
Ridker, P. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.303215 · Cited by 63
Self-citation
On- and Off-Target Pharmacology of Torcetrapib
Johns, D. G., Duffy, J., Fisher, T. S., Hubbard, B. K., & Forrest, M. J. (2012) · Drugs · doi:10.2165/11599310-000000000-00000 · Cited by 60
Rosuvastatin treatment in stable chronic obstructive pulmonary disease ( RODEO ): a randomized controlled trial
Neukamm, A. M. C., Høiseth, A. D., Einvik, G., Lehmann, S., Hagve, T., Søyseth, V., & Omland, T. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12337 · Cited by 60
Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients
Schuck, R. N., Theken, K. N., Edin, M. L., Caughey, M. C., Bass, A., Ellis, K., Tran, B. W., Steele, S., Simmons, B., Lih, F. B., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.034 · Cited by 60
Strength Training for Arthritis Trial (START): design and rationale
Messier, S. P., Mihalko, S. L., Beavers, D. P., Nicklas, B. J., DeVita, P., Carr, J. J., Hunter, D. J., Williamson, J. D., Bennell, K. L., Guermazi, A., et al. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-208 · Cited by 60
Association Between C-Reactive Protein Genotype, Circulating Levels, and Aortic Pulse Wave Velocity
Schumacher, W., Cockcroft, J., Timpson, N. J., McEniery, C. M., Gallacher, J., Rumley, A., Lowe, G. D. O., Smith, G. D., Wilkinson, I. B., & Ben‐Shlomo, Y. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.117622 · Cited by 61
Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk
Blanco‐Colio, L. M., Martı́n-Ventura, J. L., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L. A., Langer, A., Martineau, P., Hernández, G., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000250616.26308.d7 · Cited by 59
Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons
Qaseem, A., Fihn, S. D., Dallas, P., Williams, S., Owens, D. K., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00011 · Cited by 60
C-Reactive Protein Elevation and Rapid Angiographic Progression of Nonculprit Lesion in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome
Nakachi, T., Kosuge, M., Hibi, K., Ebina, T., Hashiba, K., Mitsuhashi, T., Endo, M., Umemura, S., & Kimura, K. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0185 · Cited by 60
Involvement of Inflammation and Its Resolution in Disease and Therapeutics
Alfaro, S., Acuña, V., Ceriani, R., Cavieres, M. F., Oppenheimer, C. W., & Campos‐Estrada, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810719 · Cited by 68
Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins
Skowasch, D., Schrempf, S., Preusse, C. J., Likungu, J. A., Welz, A., Lüderitz, B., & Bauriedel, G. (2005) · Heart · doi:10.1136/hrt.2005.069815 · Cited by 59
Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure
Kavsak, P. A., MacRae, A. R., Newman, A. M., Lustig, V., Palomaki, G. E., Ko, D. T., Tu, J. V., & Jaffe, A. S. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.10.025 · Cited by 59
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Rapid recycling of cholesterol: The joint biologic role of C-reactive protein and serum amyloid A
Manley, P. N., Ancsin, J. B., & Kisilevsky, R. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.10.018 · Cited by 58
Statin‐Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction
Ito, M. K., Talbert, R. L., & Tsimikas, S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.7part2.85s · Cited by 59
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study
Luca, A. D., Donati, K. D. G., Colafigli, M., Cozzi‐Lepri, A., Curtis, A. D., Gori, A., Sighinolfi, L., Giacometti, A., Capobianchi, M. R., D’Avino, A., et al. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-414 · Cited by 58
Atherosclerosis As a Systemic Disease
Lahoz, C., & Mostaza, J. M. (2007) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(07)60131-5 · Cited by 58
Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
Leucker, T. M., Weiss, R. G., Schär, M., Bonanno, G., Mathews, L. M., Jones, S. R., Brown, T. T., Moore, R. D., Afework, Y., Gerstenblith, G., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009996 · Cited by 58
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
Risk Factors Associated With Cardiovascular Events During Testosterone Administration in Older Men With Mobility Limitation
Basaria, S. S., Davda, M. N., Travison, T. G., Ulloor, J., Singh, R., & Bhasin, S. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls138 · Cited by 56
Lipoprotein (a), Inflammation, and Atherosclerosis
Fusco, S. A. D., Maggioni, A. P., Scicchitano, P., Zuin, M., D’Elia, E., & Colivicchi, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072529 · Cited by 58
Dose-Dependent Effect of Statins on the Incidence of Acute Kidney Injury After Cardiac Surgery
Mithani, S., Kuskowski, M. A., Slinin, Y., Ishani, A., McFalls, E. O., & Adabağ, S. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.10.061 · Cited by 57
Drug disease interactions: role of inflammatory mediators in disease and variability in drug response.
Kulmatycki, K. M., & Jamali, F. (2005) · PubMed · Cited by 58
Improving Assessment of Drug Safety Through Proteomics
Williams, S. A., Murthy, A. C., DeLisle, R. K., Hyde, C. L., Mälarstig, A., Ostroff, R. M., Weiss, S. J., Segal, M. R., & Ganz, P. (2017) · Circulation · doi:10.1161/circulationaha.117.028213 · Cited by 58
C‐reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow‐up
Vanhaverbeke, M., Veltman, D., Pattyn, N., Crem, N. D., Gillijns, H., Cornelissen, V., Janssens, S. P., & Sinnaeve, P. (2018) · Clinical Cardiology · doi:10.1002/clc.23017 · Cited by 57
Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial
Gholoobi, A., Askari, V. R., Naghedinia, H., Ahmadi, M., Vakili, V., & Rahimi, V. B. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00865-0 · Cited by 58
C‐reactive protein, interleukin‐6, secretory phospholipase A2 group IIA and intercellular adhesion molecule‐1 in the prediction of late outcome events after acute coronary syndromes
Hartford, M., Wiklund, O., Hultén, L. M., Persson, A., Karlsson, T., Herlitz, J. D., & Caidahl, K. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01862.x · Cited by 57

Authors: Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Ridker, Paul M
Cannon, Christopher P.
Morrow, David
Rifai, Nader
Rose, Lynda M.
Pfeffer, Marc A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-06
Volume: 352
Issue: 1
Pages: 20-28
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa042378
OpenAlex: W2118154631
Cited by: 2,292
References: 28
Citations by year: 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
FWCI: 282.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
MeSH terms: Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein Levels and Outcomes after Statin Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks